To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This is a Phase 2a randomized, double-blind (subject/investigator blinded, MedImmune unblinded), placebo-controlled, dose-escalation study to evaluate the safety, PK/PD, and immunogenicity of single IV and SC MEDI6012 doses in adult subjects with stable CAD.
Epistemonikos ID: 763815dddb305c771ec5d59031397503f2272bba
First added on: May 12, 2024